Navigation Links
Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility
Date:9/17/2008

New Facility Enables Pharmatek to Serve Growing Highly-Potent and Cytotoxic

Compound Market

SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Pharmatek -- a pharmaceutical chemistry development organization supporting the pharmaceutical industry -- today announced the opening of its highly-potent and cytotoxic facility located in San Diego.

The 18,000 sq. ft. facility includes newly constructed analytical and formulation development laboratories and cGMP manufacturing suites dedicated to the development of highly-potent and cytotoxic drug product for early phase clinical trials.

"Highly-potent and cytotoxic compounds are among the most sensitive drugs to handle and produce," said Kevin Rosenthal, director of manufacturing of Pharmatek. "Our primary goal when designing the facility was to optimize product quality while ensuring operator safety to guarantee our clients' drug candidates move smoothly from discovery to clinical trials."

The facility holds a State of California Food and Drug Branch (FDB) Drug Manufacturers License and is currently working on a number of highly-potent development projects. The FDB license authorizes Pharmatek to manufacture and ship clinical material from its state-of-the-art highly-potent and cytotoxic manufacturing and development site.

"The highly-potent facility is a significant addition to our service offering," said Timothy Scott, president of Pharmatek. "We are always looking for ways to better meet our client's drug development outsourcing needs, and the highly-potent and cytotoxic facility strengthens our ability to provide a broader level of services to our clients."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and highly-potent and cytotoxic drug development.

Statements contained in this media release which are not historical facts may

constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ

from those projected including sales forecasts and strategic expansion. The

trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry and

Pharmatek Formulation Screening are all property of Pharmatek Laboratories,

Inc. Additional information about Pharmatek Laboratories may be obtained at
the Web site http://www.pharmatek.com or by calling 858-805-6383.

Company Contact:

Elizabeth Hickman, Marketing Manager

Pharmatek Laboratories, Inc.

(858) 805-6383 x235

ehickman@pharmatek.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jeffrey A. Bibbs http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=48157 Timothy M. Scott http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=50335


'/>"/>
SOURCE Pharmatek
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
(Date:2/8/2016)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... companies in the TSX Venture 50 TM . ... TSX Venture Exchange, in each of five major industry sectors ... life sciences, diversified industries and technology – based on a ... market cap growth, trading volume and analyst coverage. All data ...
(Date:2/8/2016)... February 8, 2016 ... Limited, an innovation-driven oncology company developing next generation ... toxic, today announced that chairman emeritus of Tata ... in the company as part of the first ... existing investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... 2016  BioElectronics Corporation (OTC Pink: BIEL), the ... that it is responding to a notice of ... and Exchange Commission posted on the agency website.  ... the Board of BioElectronics Corporation and the Edward ... The Fuqua School of Business, Duke University.   ...
Breaking Biology Technology:
(Date:1/20/2016)... JOSE, Calif. , Jan. 20, 2016 /PRNewswire/ ... developer of human interface solutions, today announced sampling ... controller solution for wearables and small screen applications ... such as printers. Supporting round and rectangular shapes, ... S1423 offers excellent performance with moisture on screen, ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
(Date:1/8/2016)... , January 8, 2016 ... market and WorldVentures ® , a privately held leading ... an Inc. 5000 fastest-growing company announced that ... investment of $2 million in Nxt-ID to develop a ... on Nxt-ID,s Wocket ® , a unique smart wallet ...
Breaking Biology News(10 mins):